Aratana Therapeutics, Inc. (PETX) Shares Bought by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company raised its holdings in Aratana Therapeutics, Inc. (NASDAQ:PETX) by 25.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,176 shares of the biopharmaceutical company’s stock after buying an additional 6,898 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of Aratana Therapeutics worth $248,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Teachers Advisors LLC raised its stake in Aratana Therapeutics by 34.5% in the second quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 18,526 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,200 shares during the period. Williams Jones & Associates LLC acquired a new position in shares of Aratana Therapeutics in the second quarter valued at about $827,000. Geneva Advisors LLC increased its holdings in shares of Aratana Therapeutics by 3.7% in the second quarter. Geneva Advisors LLC now owns 80,118 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 2,830 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Aratana Therapeutics by 10.1% in the second quarter. Wells Fargo & Company MN now owns 303,988 shares of the biopharmaceutical company’s stock valued at $2,197,000 after purchasing an additional 27,836 shares during the period. Institutional investors own 73.95% of the company’s stock.
Shares of Aratana Therapeutics, Inc. (PETX) opened at $5.43 on Friday. Aratana Therapeutics, Inc. has a 1-year low of $4.97 and a 1-year high of $8.63. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26.
Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. Aratana Therapeutics’s revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same period last year, the company earned ($0.38) earnings per share. sell-side analysts anticipate that Aratana Therapeutics, Inc. will post -1.03 earnings per share for the current year.
In related news, COO Brent Standridge sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the sale, the chief operating officer now directly owns 70,267 shares of the company’s stock, valued at $429,331.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $6.53, for a total value of $760,849.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,127,032 shares of company stock worth $6,622,391. 5.20% of the stock is owned by corporate insiders.
A number of brokerages have recently weighed in on PETX. Jefferies Group set a $9.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a report on Thursday, November 16th. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Thursday, November 9th. HC Wainwright began coverage on Aratana Therapeutics in a report on Friday, November 17th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Lake Street Capital cut their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.75.
ILLEGAL ACTIVITY NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/aratana-therapeutics-inc-petx-shares-bought-by-the-manufacturers-life-insurance-company/1750998.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.